James W. Lee, MD in Moorestown, NJ ...

Dr. James W. Lee

Claim this profile

Virtua Samson Cancer Center

Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
18 reported clinical trials
27 drugs studied

About James W. Lee

Education:

  • Earned an MD from Cornell University Medical College.

Experience:

  • Board Certified in Internal Medicine and Oncology.
  • Has over 30 years of experience in patient care.
  • Joined Hematology Oncology Associates, SJ in 2004, serving the Mount Holly community.
  • Completed an internship at Georgetown University Hospital and received training at the National Cancer Institute (NCI).
  • Actively participates in clinical trials to advance cancer diagnosis and treatment techniques.

Area of expertise

1

Lung Cancer

Global Leader

James W. Lee has run 15 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Non-Small Cell Lung Cancer

Global Leader

James W. Lee has run 13 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.

Virtua Samson Cancer Center

Image of trial facility.

Virtua Voorhees

Clinical Trials James W. Lee is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Tepotinib + Ramucirumab

for Lung Cancer

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.

Recruiting

1 award

Phase 2

4 criteria

More about James W. Lee

Clinical Trial Related

5 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments James W. Lee has experience with

  • Pembrolizumab
  • Carboplatin
  • Ramucirumab
  • Pemetrexed
  • Selpercatinib
  • Pemetrexed Disodium

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does James W. Lee specialize in?

Is James W. Lee currently recruiting for clinical trials?

Are there any treatments that James W. Lee has studied deeply?

What is the best way to schedule an appointment with James W. Lee?

What is the office address of James W. Lee?

Is there any support for travel costs?